Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Syndax Pharmaceuticals (SNDX) EBITDA Margin (2016 - 2020)

Historic EBITDA Margin for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to 5226.32%.

  • Syndax Pharmaceuticals' EBITDA Margin fell 14881600.0% to 5226.32% in Q4 2020 from the same period last year, while for Dec 2020 it was 4708.17%, marking a year-over-year decrease of 9152300.0%. This contributed to the annual value of 1434.43% for FY2024, which is N/A changed from last year.
  • As of Q4 2020, Syndax Pharmaceuticals' EBITDA Margin stood at 5226.32%, which was down 14881600.0% from 5238.26% recorded in Q3 2020.
  • In the past 5 years, Syndax Pharmaceuticals' EBITDA Margin ranged from a high of 1633.61% in Q4 2017 and a low of 5238.26% during Q3 2020
  • Over the past 5 years, Syndax Pharmaceuticals' median EBITDA Margin value was 4327.19% (recorded in 2017), while the average stood at 4199.42%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 338655200bps in 2016, then tumbled by -34540200bps in 2018.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' EBITDA Margin stood at 3652.79% in 2016, then surged by 55bps to 1633.61% in 2017, then plummeted by -211bps to 5087.63% in 2018, then rose by 27bps to 3738.16% in 2019, then crashed by -40bps to 5226.32% in 2020.
  • Its EBITDA Margin was 5226.32% in Q4 2020, compared to 5238.26% in Q3 2020 and 4382.59% in Q2 2020.